在接受治疗耐药抑郁症治疗的患者中,神经认知变化
Carolyn F Kundert1, Robert M Sobule, Muaid Ithman
1At the University of Missouri-Columbia, Carolyn F. Kundert practices in psychiatry and is associate director of the Advanced Practice Provider (APP) Psychiatry Fellowship, Robert M. Sobule is director of the APP Psychiatry Fellowship and chief APP, and Muaid Ithman is vice chair for clinical operations in the Department of Psychiatry and an associate professor of psychiatry. The authors have disclosed no potential conflicts of interest, financial or otherwise.
概括
用于治疗耐药抑郁症的Esketamine鼻喷雾剂可能会使某些患者的认知副作用恶化. 这一案例凸显了在治疗中需要进行神经认知监测的必要性.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 乙胺,乙胺的S(+) 反体,是一种FDA批准的治疗耐治疗抑郁症 (TRD) 的鼻入药物.
- 与抗抑郁药一起使用,胺在临床环境中是自我使用的,并且通常耐受良好.
- 常见的不良反应通常是轻微的,短暂的,并且依赖于剂量.
研究的目的:
- 报告TRD治疗期间神经认知症状恶化的病例.
- 要突出潜在的认知不良影响在初始患者评估期间不经常评估.
主要方法:
- 病例报告详细介绍了一名患者对TRD的埃斯基他治疗的经验.
- 对患者在治疗期间神经认知症状进展的审查.
主要成果:
- 患者经历了神经认知症状的恶化,包括记忆和思维困难,随着持续使用esketamine.
- 这些认知症状需要停止治疗.
结论:
- 虽然通常是安全的,但埃斯基他胺治疗可能会导致敏感个体显著的神经认知不良影响.
- 神经认知评估可能是必要的,作为初始评估和持续监测的一部分,为患者接受esketamine.
- 需要进一步研究胺胺的长期神经认知效应.
相关概念视频
01:30Electroconvulsive Therapy
29
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
29
01:23Antidepressant Drugs: MAOIs and Other Agents
205
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
205
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
337
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
337